Evaluation of the Interaction Between Wharton's Jelly-Derived Mesenchymal Stem Cells and β-Mercaptoethanol
Öz Bağcı F., Özgörgülü A., Çiçek G., Utlu Özen E., Duman S., Aktan TM.
Laboratory Study on Spinal Cord Injury, Neuroinflammation, published in Cureus (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Cureus (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40438831
- PMCID
- PMC12117518
- DOI
- 10.7759/cureus.83115
- Citations
- 2
Abstract (original English)
Purpose Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are self-regenerative and able to differentiate into multipotent stem cells. There may be different sources of mesenchymal stem cells (MSCs) involved in the repair mechanism of damaged tissues in the organism. WJ-MSCs may differentiate into osteocytes, chondrocytes, adipocytes, and myocyte cells. Furthermore, MSCs show neuroprotective effects on neurons. Today, many MSC neuroregenerative treatments have been shown to be effective. Studies have shown that MSCs are more involved in paracrine effects due to their neuroprotective effect in multiple diseases such as multiple sclerosis, acute spinal cord injury and encephalomyelitis. The main aim of this study was to investigate the neuronal markers of stem cells after incubation with β-mercaptoethanol (BME). Materials and methods In our study, WJ-MSCs were thawed in a water bath at 37°C and cultivated in cell culture dishes. When the cell occupancy rate reached 60-70%, they were treated with 2 mM BME. At the first and third hours, MSCs were removed from the dishes, and flow cytometry and immunostaining revealed that BME's nestin, neuron filament light (NF-L), SOX1, SOX2, doublecortin (DCX), glial fibrillary acidic protein (GFAP), Ki67, and CD44 were evaluated. Results Immunocytochemically, nestin and NF-L values of MSCs exposed to BME increased at the first hour. In
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic ReviewPubMed
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell3 citations - Level ASystematic ReviewEurope PMC
Revolutionizing neural regeneration with smart responsive materials: Current insights and future prospects
Systematic Review on Spinal Cord Injury, published in Bioact Mater (2025) — summary generated from the PubMed abstract.
- 2025
Bioact Mater5 citations - Level ASystematic ReviewEurope PMC
Conductive Nanocomposite Hydrogels for Neural Tissue Engineering: A Systematic Scoping Review of Recent Trends
Systematic Review with a reported sample of 42 on Diabetic Foot, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
- 2025
- n = 42
Adv Sci (Weinh)18 citations - Level ASystematic ReviewEurope PMC
Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights
Systematic Review on Spinal Cord Injury, Neuroinflammation, published in Front Neurosci (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurosci